<DOC>
	<DOCNO>NCT00359437</DOCNO>
	<brief_summary>Primary To evaluate efficacy satavaptan top diuretic drug reduce recurrence ascites . Secondary To evaluate tolerability safety satavaptan top diuretic drug 52-week treatment period participant cirrhosis liver recurrent ascites . The one-year double blind placebo control period extend 2 year long term safety study ( PASCCAL-2 ) .</brief_summary>
	<brief_title>Satavaptan Prevention Ascites Recurrence Patients With Ascites Due Cirrhosis Liver</brief_title>
	<detailed_description />
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Satavaptan</mesh_term>
	<criteria>Participants cirrhosis liver . Participants recurrent ascites undergone following : therapeutic paracentesis removal ascites previous 24 hour removal &gt; 4 litre fluid . least one therapeutic paracentesis previous 3 month . Participants exist functional transjugular intrahepatic portosystemic shunt ( TIPS ) shunt . Known hepatocellular carcinoma . Participants ascites cardiac origin due peritoneal infection ( e.g . tuberculosis ) peritoneal carcinoma . Participants previously expose satavaptan past 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>